CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) had its price objective raised by Stifel Nicolaus from $27.00 to $30.00 in a report published on Monday morning. Stifel Nicolaus currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on the stock. Piper Jaffray Cos. reiterated a buy rating and set a $36.00 price target on shares of CoLucid Pharmaceuticals in a research note on Thursday, September 15th. Zacks Investment Research lowered shares of CoLucid Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, September 9th. Finally, Ladenburg Thalmann boosted their price target on shares of CoLucid Pharmaceuticals from $23.00 to $52.00 and gave the stock a buy rating in a research note on Tuesday, September 6th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $30.45.

Shares of CoLucid Pharmaceuticals (NASDAQ:CLCD) opened at 33.21 on Monday. The firm’s market cap is $509.24 million. The stock’s 50 day moving average is $14.60 and its 200-day moving average is $9.03. CoLucid Pharmaceuticals has a one year low of $3.57 and a one year high of $35.48.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.22. Analysts anticipate that CoLucid Pharmaceuticals will post ($3.91) EPS for the current fiscal year.

In other CoLucid Pharmaceuticals news, CEO Thomas P. Mathers sold 6,000 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $23.32, for a total value of $139,920.00. Following the sale, the chief executive officer now owns 244,714 shares of the company’s stock, valued at $5,706,730.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $8.45, for a total transaction of $1,293,086.60. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in CLCD. FMR LLC acquired a new stake in shares of CoLucid Pharmaceuticals during the second quarter valued at about $554,000. Vanguard Group Inc. increased its stake in shares of CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 900 shares during the period. Finally, Societe Generale acquired a new stake in shares of CoLucid Pharmaceuticals during the second quarter valued at about $464,000. 36.92% of the stock is currently owned by institutional investors.

CoLucid Pharmaceuticals Company Profile

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

5 Day Chart for NASDAQ:CLCD

Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.